Download PDF
Thromb Haemost 1997; 78(01): 079-082
DOI: 10.1055/s-0038-1657505
Antiphospholipid antibodies
Schattauer GmbH Stuttgart

Thrombogenic Mechanisms of Antiphospholipid Antibodies

Naomi L Esmon
Oklahoma Medical Research Foundation, Departments of Biochemistry and Molecular Biology, and Pathology; University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, OK, USA
,
Mikhail D Smirnov
Oklahoma Medical Research Foundation, Departments of Biochemistry and Molecular Biology, and Pathology; University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, OK, USA
,
Charles T Esmon
Oklahoma Medical Research Foundation, Departments of Biochemistry and Molecular Biology, and Pathology; University of Oklahoma Health Sciences Center, Howard Hughes Medical Institute, Oklahoma City, OK, USA
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints
 

  • References

  • 1 Triplett DA. Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause?. Arch Pathol Lab Med 1993; 117: 78-88
    PubMedGoogle Scholar
  • 2 Esmon NL, Smirnov MD, Esmon CT. Lupus anticoagulants and thrombosis: The role of phospholipids. [In Press] Haematologia. 1997
    Google Scholar
  • 3 Roubey RAS. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other “antiphospholipid” autoantibodies. Blood 1994; 84: 2854-2867
    PubMedGoogle Scholar
  • 4 Sugi T, McIntyre JA. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost 1996; 76: 354-360
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Mohan Rao LV, Hoang AD, Rapaport SI. Mechanism and effects of the binding of lupus anticoagulant IgG and prothrombin to surface phospholipid. Blood 1996; 88: 4173-4182
    PubMedGoogle Scholar
  • 6 Hörkkö S, Miller E, Dudl E, Reaven P, Curtiss LK, Zvaifler NJ, Terkeltaub R, Pierangeli SS, Branch DW, Palinski W. et al Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest 1996; 98: 815-825
    CrossrefPubMedGoogle Scholar
  • 7 Arvieux J, Damige L, Caron C, Reber G, Bensa JC, Colomb MG. Development of an ELISA for autoantibodies to prothrombin showing their prevalence in patients with lupus anticoagulants. Thromb Haemost 1995; 74: 1120-1125
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, Acland R, Harris EN. Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice. Thromb Haemostas 1994; 71: 670-674
    PubMedGoogle Scholar
  • 9 Branch DW, Rodgers GM. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 1993; 168: 206-210
    CrossrefPubMedGoogle Scholar
  • 10 Stegnar M, Bozic B, Peternel P, Kveder T, Vene N, Rozman B. Prevalence of antiphospholipid antibodies in deep vein thrombosis and their relationship to blood coagulation and fibrinolysis. Thromb Res 1991; 63: 433-443
    CrossrefPubMedGoogle Scholar
  • 11 Kimberly RP, Salmon JE, Edberg JC. Receptors for immunoglobulin G. Molecular diversity and implications for disease. Arthritis Rheum 1995; 38: 306-314
    CrossrefPubMedGoogle Scholar
  • 12 Salmon JE, Edberg JC, Brogle NL, Kimberly RP. Allelic polymorphisms of human Fcgamma receptor IIA and Fcgamma receptor IIIB: Independent mechanisms for differences in human phagocyte function. J Clin Invest 1992; 89: 1274-1281
    CrossrefPubMedGoogle Scholar
  • 13 Gibson J, Nelson M, Brown R, Salem H, Kronenberg H. Autoantibodies to thrombomodulin: Development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 1992; 67: 507-509
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, de Groot PG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism?. Blood 1993; 81: 2618-2625
    CrossrefPubMedGoogle Scholar
  • 15 Bokarewa M. Phospholipid antibodies and APC resistance phenomenon in patients with thrombosis. Ph.D Thesis. Karolinska Institute. 1995
    Google Scholar
  • 16 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Sem Hematol 1992; 29: 213-226
    PubMedGoogle Scholar
  • 17 Berard M, Chantome R, Marcelli A, Boffa M-C. Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies.I. Association with thrombosis and vascular cutaneous diseases. J Rheumatol 1996; 23: 1369-1374
    PubMedGoogle Scholar
  • 18 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-819
    CrossrefPubMedGoogle Scholar
  • 19 Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-316
    CrossrefPubMedGoogle Scholar
  • 20 Smeets EF, Comfurius P, Bevers EM, Zwaal RFA. Contribution of different phospholipid classes to the prothrombin converting capacity of sonicated lipid vesicles. Thromb Res 1996; 81: 419-426
    CrossrefPubMedGoogle Scholar
  • 21 Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH. Phosphatidylethanolamine augments factor VHa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34: 13988-13993
    CrossrefPubMedGoogle Scholar
  • 22 Gilbert GE, Arena AA. Phosphatidylethanolamine induces high affinity binding sites for factor VIII on membranes containing phosphatidyl-L-serine. J Biol Chem 1995; 270: 18500-18505
    CrossrefPubMedGoogle Scholar
  • 23 Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53: 505-518
    CrossrefPubMedGoogle Scholar
  • 24 Smirnov M, Rezaie AR, Regan LM, Esmon CT, Esmon NL. The PE dependence of activated protein C function is mediated through the gla-domain. [Abstract] Circulation 1996; 94: 001-694
    CrossrefPubMedGoogle Scholar
  • 25 Furie B, Diuguid CF, Jacobs M, Diuguid DL, Furie BC. Randomized prospective trial comparing the native prothrombin antigen with the prothrombin time for monitoring oral anticoagulant therapy. Blood 1990; 75: 344-349
    PubMedGoogle Scholar
  • 26 Esmon CT, Schwarz HP. An update on clinical and basic aspects of the protein C anticoagulant pathway. Trends Cardiovasc Med 1995; 5: 141-148
    CrossrefPubMedGoogle Scholar